Phase 2Active, not recruiting
Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
A Phase II Trial of Daratumumab, Lenalidomide and Dexamethasone (DRd) in Combination With Selinexor for Patients With Newly Diagnosed Multiple Myeloma
- Sponsor
- US Oncology Research (Industry)
- Enrollment
- 73 enrolled
- Conditions
- Multiple Myeloma; Myeloma Multiple; Kahler Disease; Myeloma, Plasma Cell; Myeloma-Multiple; Myelomatosis; Plasma Cell Myeloma
- Interventions
- Selinexor; Dexamethasone Oral; Daratumumab; Lenalidomide
- Ages
- adults, older adults
- Registry
- NCT04782687
Full record on ClinicalTrials.gov
From the registry
This is a single-arm, phase II, open-label trial to investigate the effects of selinexor (S) in combination with daratumumab, lenalidomide, and dexamethasone (DRd) for first-line treatment of multiple myeloma (MM). FDA has approved selinexor plus dexamethasone in multiple myeloma after four prior therapies, and DRd is also already approved by the FDA for multiple myeloma. This study will use all four (S-DRd) together to treat MM as an initial treatment.
Primary outcomes
- Complete Response Rate (CR)
- Stringent Complete Response Rate (sCR)
- Safety of Selinexor plus DRd
History
Primary completion
Last registry update
Started
Registered